Clinical and genetic characteristics of our study population and prognostic value by univariate Cox regression test
| Mean (SD) or No. (%) | Hazard Ratio (95% CI) | P Value | |
|---|---|---|---|
| Age (years) | 55.5 (13.4) | 1.02 (0.990–1.06) | .172 |
| Sex | |||
| Men | 21 (63.6%) | 0.887 (0.393–2.00) | .772 |
| Women | 12 (36.4%) | ||
| Radiation dose | |||
| Hypofractionated (45 Gy in 15 fractions) | 6 (18.2%) | 1.51 (0.593–3.84) | .388 |
| Conventional long course (>60 Gy) | 27 (81.8%) | ||
| Karnofsky Performance Status score | |||
| <70 | 3 (9.1%) | 0.820 (0.193–3.50) | .789 |
| ≥70 | 30 (90.9%) | ||
| IDH1 or 2 mutation | |||
| Present | 2 (6.1%) | 0.324 (0.0432–2.436) | .274 |
| Absent | 31 (93.9%) | ||
| MGMT promoter methylation | |||
| Methylated | 22 (66.7%) | 0.256 (0.113–0.577) | .001 |
| Unmethylated | 11 (33.3%) | ||
| Baseline T2 high-signal-intensity volume (mL) | 59.5 (29.0) | 0.996 (0.982–1.01) | .573 |
| Posttreatment T2 high-signal-intensity volume (mL) | 16.6 (24.8) | 0.996 (0.978–1.01) | .668 |
| Percentage change T2 high-signal-intensity volume | −64.3% (44.8%) | 1.04 (0.412–2.63) | .934 |